The advent of new targeted oral therapies to treat moderate-severe psoriasis generated anticipation about their impact on the existing biologic treatment paradigm. Top-level insights from Ipsos’ PsO Therapy Monitor highlight key physician-stated and real-world patient metrics to consider when planning for launch of a new asset or defending an existing asset in this market.
A series of three reports that brings the nasal polyps patient voice directly to pharma. Spanning 18 months, Ipsos’ Severe Nasal Polyps Patient Community provides unique visibility of patients’ unmet needs via an ongoing online panel of those living with the condition. Interactive activities focused on specific elements of their journey, offering insights to support a patient-centric strategy.
Since 2018, several new advanced therapies of differing mechanisms of action have been launched in the moderate-severe UC and CD treatment landscapes ‑ some being oral options. Top-level insights from Ipsos’ IBD Therapy Monitor highlight key physician-stated and real-world patient metrics to consider when planning for launch of a new asset or defending an existing asset in this market.
Ipsos' Social Intelligence Analytics report delivers novel insights into the authentic patient experience, analysing over 9,000 social media posts and forum discussions across global platforms. The findings highlight critical disconnects in the AD patient journey, enabling companies to develop targeted solutions that address true patient needs, enhance treatment adherence, and strengthen market positioning.
A series of five reports that brings the asthma patient voice directly to pharma. Conducted over two years, Ipsos’ Severe Asthma Patient Community offers unique visibility of patients’ unmet needs via an ongoing online panel of those living with the condition. Interactive activities focused on specific elements of the asthma patient journey, offering insights to support a patient-centric strategy.
A series of seven reports that brings the AD patient voice directly to pharma. Conducted over three years, Ipsos’ AD Patient & Caregiver Community offers unique visibility of patients’ unmet needs via an ongoing online panel of those living with the condition ‑ plus those caring for children with AD. Interactive activities focused on specific elements of the AD patient journey, offering insights to support a patient-centric strategy.
With the advent of biologic and JAK inhibitor medications for atopic dermatitis within the last decade, this therapeutic landscape has been fundamentally shifting. Trended data analysis from Ipsos’ Atopic Dermatitis Therapy Monitor provides an unparalleled view of the impact of these new entrants across multiple facets, including real-world prescribing habits, patient journey modifications and influences on HCP attitudes and behaviour.
By leveraging real-world patient data from Ipsos' Ophthalmology Therapy Monitor and applying CHAID segmentation analysis, specific patient clusters where HCPs demonstrate clear preferences between anti-VEGF drugs and steroids are identified. Clear mapping of the decision pathways that influence prescribing behaviour in DME and RVO are realised.